| 000 | 04671cam a2200697Ii 4500 | ||
|---|---|---|---|
| 001 | ocn779616898 | ||
| 003 | OCoLC | ||
| 005 | 20171115090956.0 | ||
| 006 | m o d | ||
| 007 | cr ||||||||||| | ||
| 008 | 120309t20122012gw a ob 001 0 eng d | ||
| 020 |
_a9783527644827 _q(oBook) |
||
| 020 |
_a3527644822 _q(oBook) |
||
| 020 |
_a9783527644797 _q(ePDF) |
||
| 020 |
_a3527644792 _q(ePDF) |
||
| 020 |
_a9783527644780 _q(ePub) |
||
| 020 |
_a3527644784 _q(ePub) |
||
| 020 |
_a9783527644803 _q(Mobi) |
||
| 020 |
_a3527644806 _q(Mobi) |
||
| 020 | _a128345422X | ||
| 020 | _a9781283454223 | ||
| 020 |
_z9783527328499 _q(print ; _qalk. paper) |
||
| 020 |
_z3527328491 _q(print ; _qalk. paper) |
||
| 029 | 1 |
_aAU@ _b000049014070 |
|
| 029 | 1 |
_aDKDLA _b820120-katalog:000601021 |
|
| 029 | 1 |
_aNZ1 _b14694101 |
|
| 029 | 1 |
_aNZ1 _b15916291 |
|
| 029 | 1 |
_aDEBBG _bBV043394342 |
|
| 029 | 1 |
_aAU@ _b000059228061 |
|
| 035 |
_a(OCoLC)779616898 _z(OCoLC)778622647 _z(OCoLC)781540190 _z(OCoLC)785779913 _z(OCoLC)817058699 _z(OCoLC)824108355 _z(OCoLC)961501435 _z(OCoLC)962591607 |
||
| 037 |
_a10.1002/9783527644827 _bWiley InterScience _nhttp://www3.interscience.wiley.com |
||
| 040 |
_aDG1 _beng _erda _epn _cDG1 _dN$T _dE7B _dYDXCP _dOCLCQ _dOCLCF _dMMU _dOCLCQ _dOCLCO _dNLGGC _dIDEBK _dCOO _dOCLCQ _dDEBBG _dEBLCP |
||
| 049 | _aMAIN | ||
| 050 | 4 | _aRS431.P75 | |
| 060 | 4 | _aQU 55 | |
| 072 | 7 |
_aMED _x071000 _2bisacsh |
|
| 082 | 0 | 4 |
_a615.3 _223 |
| 245 | 0 | 0 |
_aTherapeutic proteins : strategies to modulate their plasma half-lives / _cedited by Roland Kontermann. _h[electronic resource] |
| 264 | 1 |
_aWeinheim, Germany : _bWiley-Blackwell, an imprint of John Wiley & Sons, _c2012. |
|
| 264 | 4 | _c©2012 | |
| 300 |
_a1 online resource (374 pages) : _billustrations (some color) |
||
| 336 |
_atext _btxt _2rdacontent |
||
| 337 |
_acomputer _bc _2rdamedia |
||
| 338 |
_aonline resource _bcr _2rdacarrier |
||
| 504 | _aIncludes bibliographical references and index. | ||
| 505 | 0 | _aGeneral information -- Half-life modulating strategies : an introduction -- Pharmacokinetics and half-life of protein therapeutics -- Half-life extension through chemical and post-translational modifications -- Half-life extension through PEGylation -- Half-life extension of therapeutic proteins via genetic fusion to recombinant PEG mimetics -- Half-life extension through O-glycosylation -- Polysialic acid and polysialylation to modulate antibody pharmacokinetics -- Half-life extension through HESylation -- Half-life modulation involving recycling by the neonatal Fc receptor -- The biology of the neonatal Fc receptor (FcRn) -- half-life extension by fusion to the Fc region -- Monomeric Fc fusion technology: an approach to create long-lasting clotting factors -- The diverse roles of FcRn: implications for antibody engineering -- Half-life extension by fusion to recombinant albumin -- AlbudAb technology platform: versatile albumin binding domains for the development of therapeutics with tunable half-lives -- Half-life extension by binding to albumin through an albumin binding domain -- Half-life extension by binding to albumin through small molecules -- Half-life extension with pharmaceutical formulations -- Half-life extension with pharmaceutical formulations: liposomes -- Half-life extension with pharmaceutical formulations: nanoparticles by the miniemulsion process. | |
| 520 | _aFor this ready reference, the internationally renowned authority in the field, Roland Kontermann, has assembled a team of outstanding contributors from industry and academia to convey the worldwide knowledge on modifying therapeutic proteins in order to optimize their pharmacological potential. The result is a comprehensive work covering all approaches and aspects of the topic in one handy volume, making this indispensable reading for companies and research institutions working on the development of biopharmaceuticals. | ||
| 588 | 0 | _aOnline resource; title from resource home page (ebrary, viewed on June 17, 2014). | |
| 650 | 0 |
_aProtein drugs _xDesign. |
|
| 650 | 0 |
_aProteins _xTherapeutic use. |
|
| 650 | 2 |
_aProteins _xpharmacokinetics. |
|
| 650 | 2 | _aHalf-Life. | |
| 650 | 7 |
_aMEDICAL _xPharmacology. _2bisacsh |
|
| 650 | 7 |
_aProtein drugs _xDesign. _2fast _0(OCoLC)fst01079680 |
|
| 650 | 7 |
_aProteins _xTherapeutic use. _2fast _0(OCoLC)fst01079767 |
|
| 655 | 4 | _aElectronic books. | |
| 700 | 1 |
_aKontermann, Roland, _d1961- _eeditor. |
|
| 776 | 0 | 8 |
_iPrint version: _tTherapeutic proteins. _dWeinheim, Germany : Wiley-VCH, ©2011 _z9783527328499 _w(DLC) 2012540834 _w(OCoLC)768072878 |
| 856 | 4 | 0 |
_uhttp://onlinelibrary.wiley.com/book/10.1002/9783527644827 _zWiley Online Library |
| 942 |
_2ddc _cBK |
||
| 999 |
_c205704 _d205704 |
||